

Diabetes 2030 Forecasts, 2015

PHILADELPHIA Metropolitan Area Diabetes Data & Forecasts

Includes: Philadelphia-Camden-Wilmington, PA-NJ-DE-MD Metropolitan Statistical Area

Metro Total Population Forecasts	2015	2020	2025	2030
Entire Population	5,979,000	6,050,100	6,091,100	6,240,200
Prediabetes	1,623,000	1,696,400	1,759,000	1,804,500
Diagnosed diabetes	511,800	613,400	694,300	768,000
Undiagnosed diabetes	168,500	191,900	206,000	215,900
Total with diabetes (diagnosed and undiagnosed)	680,300	805,200	900,300	983,900
Complications:				
Visual impairment	83,900	97,600	107,300	115,200
Renal failure	1,220	1,410	1,540	1,640
Leg amputations	1,060	1,170	1,210	1,240
Annual deaths attributable to diabetes	5,510	6,310	6,780	7,100
Total annual cost (2015 dollars)	\$7.1 B	\$8.3 B	\$9.3 B	\$10.2 B
Annual medical costs	\$5.3 B	\$6.2 B	\$6.9 B	\$7.6 B
Annual nonmedical costs	\$1.8 B	\$2.1 B	\$2.4 B	\$2.6 B

Metro Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	1,032,900	1,152,500	1,268,500	1,410,300
Prediabetes	526,800	587,800	646,900	719,200
Diagnosed diabetes	195,200	217,800	239,700	266,500
Undiagnosed diabetes	72,300	80,700	88,800	98,700
Total with diabetes (diagnosed and undiagnosed)	267,500	298,500	328,500	365,300
Complications:				
Visual impairment	36,500	39,700	42,600	46,100
Renal failure	600	650	690	740
Leg amputations	450	470	470	490
Annual deaths attributable to diabetes	3,800	4,230	4,410	4,470
Total annual cost (2015 dollars)	\$3.4 B	\$3.8 B	\$4.2 B	\$4.7 B
Annual medical costs	\$3.2 B	\$3.6 B	\$3.9 B	\$4.4 B
Annual nonmedical costs	\$0.2 B	\$0.2 B	\$0.3 B	\$0.3 B

These forecasts are based on the latest available national diabetes data, including U.S. Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit www.altfutures.org/diabetes2030.

Research funded by Novo Nordisk Inc.